Taysha Gene Therapies, Inc. (TSHA) News
Follow Taysha Gene Therapies, Inc. (TSHA) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 18 public stories across 11 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
M
Taysha Gene Therapies Q3'26 Revenue Estimate Is 755.56K USD
Q3'26 results are expected November 10; revenue is estimated at 755.56 thousand USD and EPS at (0.13) USD. The release time is not specified.
EQUITY | Nov 03, 2026, 12:01 PM UTC
L
Taysha Gene Therapies announces Nasdaq inducement grant under Rule 5635(c)(4)
Taysha Gene Therapies, Inc. announced an inducement grant under Nasdaq Listing Rule 5635(c)(4).
EQUITY | Sep 04, 2026, 12:07 PM UTC
L
TSHA announces inducement grant under Nasdaq Rule 5635(c)(4)
Taysha Gene Therapies said it announced an inducement grant under Nasdaq Listing Rule 5635(c)(4).
EQUITY | Sep 04, 2026, 12:00 PM UTC
L
Taysha Gene Therapies Q2 EPS $(0.13) Misses $(0.12) Estimate
Taysha Gene Therapies (NASDAQ: TSHA ) reported quarterly losses of $(0.13) per share which missed the analyst consensus estimate of $(0.12) by 8.33 percent. This is a 44.44 percent decrease over losses of $(0.09) per sha
EARNINGS | Aug 11, 2026, 08:00 PM UTC
L
TSHA - Taysha Gene Therapies Reports Second Quarter 2026 Financial Results and Provides Corporate Update
TSHA - Taysha Gene Therapies Reports Second Quarter 2026 Financial Results and Provides Corporate Update
EARNINGS | Aug 11, 2026, 08:00 PM UTC
L
TSHA - Taysha Gene Therapies to Release Second Quarter 2026 Financial Results and Host Conference Call and Webcast on August 11 - Click For
TSHA - Taysha Gene Therapies to Release Second Quarter 2026 Financial Results and Host Conference Call and Webcast on August 11
EARNINGS | Aug 04, 2026, 08:00 PM UTC
M
Taysha Expands Catalent Partnership
Taysha partners with Catalent for manufacturing support
EQUITY | Aug 03, 2026, 12:00 PM UTC
L
Taysha Gene Therapies Insider Sold Shares Worth $1,248,000, According to a Recent SEC Filing
() -- Sukumar Nagendran, Director, President and Head of Research and Development, on July 10, 2026, sold 200,000 shares in Taysha Gene Therapies (TSHA) for $1,248,000. Following the Form 4 filing with the SEC, Nagendran
GEOPOLITICS | Jul 13, 2026, 07:58 AM UTC
L
Citizens Reiterates Market Outperform on Taysha Gene Therapies, Maintains $11 Price Target
Citizens analyst Silvan Turkcan reiterates Taysha Gene Therapies (NASDAQ: TSHA ) with a Market Outperform and maintains $11 price target.
EQUITY | Jul 02, 2026, 12:56 PM UTC
L
Baird Maintains Outperform on Taysha Gene Therapies, Raises Price Target to $15
Baird analyst Jack Allen maintains Taysha Gene Therapies (NASDAQ: TSHA ) with a Outperform and raises the price target from $12 to $15.
EQUITY | Jun 30, 2026, 11:50 AM UTC
M
TSHA Presents TSHA-102 Data
Taysha Gene Therapies announces multiple presentations highlighting its TSHA-102 clinical program at the 2026 IRSF Rett Syndrome Scientific Meeting
EQUITY | Jun 25, 2026, 08:01 PM UTC
H
SPRY -24% on Update
SPRY falls 24% premarket after providing commercial and financial updates, while other big cap stocks also decline on various news
EQUITY | Jun 25, 2026, 12:17 PM UTC
M
FUL, TCOM, HTZ Drop
H.B. Fuller, Trip.com, and Hertz Global are among the stocks moving lower in Thursday's pre-market session
EQUITY | Jun 25, 2026, 12:08 PM UTC
M
ALOY: Prices $100M Private Placement
ALOY prices private placement of common stock for gross proceeds of approximately $100 million
EQUITY | Jun 25, 2026, 09:49 AM UTC
M
TSHA Prices Public Offering
Taysha Gene Therapies announces pricing of public offering of common stock and pre-funded warrants
EQUITY | Jun 25, 2026, 09:11 AM UTC
M
EXR Prices $550M Notes
EXR prices $550 million of 4.900% senior notes due 2032, while ISPC files Form S-1 and TSHA proposes public offering of common stock and pre-funded warrants
EQUITY | Jun 24, 2026, 09:04 PM UTC
M
TSHA Launches Stock Offering
Taysha Gene Therapies announces proposed public offering of common stock and pre-funded warrants
EQUITY | Jun 24, 2026, 08:01 PM UTC
M
TSHA Completes Dosing
Taysha Gene Therapies completes dosing in REVEAL pivotal trial and reports longer-term clinical data from Part A of REVEAL Phase 1/2 trials for TSHA-102
EQUITY | Jun 22, 2026, 12:02 PM UTC